Literature summary for 3.4.23.16 extracted from

Dekhtyar, T.; Ng, T.I.; Lu, L.; Masse, S.; DeGoey, D.A.; Flosi, W.J.; Grampovnik, D.J.; Klein, L.L.; Kempf, D.J.; Molla, A.
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742 (2008), Antimicrob. Agents Chemother., 52, 1337-1344.

Search for more literature for 3.4.23.16

Protein Variants

Protein Variants	Comment	Organism
I84V	HIV-1 pNL4-3 clones with a single V82L or I84V mutation are phenotypically resistant to A-790742 and ritonavir	Human immunodeficiency virus 1
V82L	HIV-1 pNL4-3 clones with a single V82L or I84V mutation are phenotypically resistant to A-790742 and ritonavir	Human immunodeficiency virus 1

Inhibitors

Inhibitors	Comment	Organism	Structure
A-790742	50% effective concentration ranges from 2 to 7 nM against wild-type HIV-1. The activity is lowered by approximately 7fold in the presence of 50% human serum. A-790742 maintains potent antiviral activity against lopinavir-resistant variants generated in vitro as well as against a panel of molecular clones containing proteases derived from HIV-1 patient isolates with multiple protease mutations. HIV-1 pNL4-3 clones with a single V82L or I84V mutation are phenotypically resistant to A-790742 and ritonavir	Human immunodeficiency virus 1
ritonavir	HIV-1 pNL4-3 clones with a single V82L or I84V mutation are phenotypically resistant to A-790742 and ritonavir	Human immunodeficiency virus 1

Organism

Organism	UniProt	Comment	Textmining
Human immunodeficiency virus 1	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)